Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
275 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
RSS Create an RSS feed from your search for:
United States, Texas | United States, Texas | cook children's
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis
Condition: Candidemia
Interventions: Drug: anidulafungin;   Drug: fluconazole
2 Recruiting National Marrow Donor Program Long-Term Donor Follow-Up
Condition: Hematologic Neoplasms
Intervention:
3 Unknown  Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Conditions: Septic Shock;   Thrombocytopenia;   Multiple Organ Failure
Intervention:
4 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
5 Recruiting Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Condition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: Drug: UX007 (triheptanoin);   Drug: Placebo Oil
6 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
7 Unknown  Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
Condition: Growth Hormone Deficiency
Intervention: Drug: Somatropin
8 Enrolling by invitation Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Intervention: Drug: flecainide
9 Recruiting Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide/LXS Oral Powder;   Drug: Ketoconazole;   Drug: Vincristine
10 Recruiting Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Conditions: Vaso-occlusive Crisis;   Sickle Cell Disease
Interventions: Drug: MST-188;   Drug: Saline
11 Completed
Has Results
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Conditions: Sickle Cell Disease;   Iron Overload;   Hemolytic Anemia
Interventions: Drug: Deferasirox (ICL670);   Drug: Deferoxamine (DFO)
12 Completed
Has Results
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Condition: Patent Ductus Arteriosus (PDA)
Interventions: Device: Device closure with AMPLATZER Duct Occluder;   Other: Objective Performance Criteria
13 Active, not recruiting Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   NK Cell Lymphoblastic Leukemia
Interventions: Biological: Single Cord Blood Unit Transplantation;   Biological: Double Cord Blood Unit Transplantation
14 Recruiting An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Condition: Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Intervention: Drug: Triheptanoin
15 Active, not recruiting Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Conditions: Adult Malignant Mesenchymoma;   Adult Rhabdomyosarcoma;   Alveolar Childhood Rhabdomyosarcoma;   Childhood Malignant Mesenchymoma;   Embryonal Childhood Rhabdomyosarcoma;   Embryonal-botryoid Childhood Rhabdomyosarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma
Interventions: Drug: irinotecan hydrochloride;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis;   Other: questionnaire administration
16 Suspended Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Lenalidomide;   Other: Pharmacological Study
17 Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
18 Completed
Has Results
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor;   Drug: Placebo
19 Recruiting Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
20 Completed
Has Results
Rituximab to Treat Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years